Proactive Investors - Run By Investors For Investors

Namaste Technologies inks deal with Kief Cannabis for artisan-crafted cannabis

The craft-style cannabis will be sold through Cannmart, Namaste's e-commerce platform
Marijuana in a glass jar
Kief Cannabis develops cannabis in small batches for the high-end recreational market

Namaste Technologies Inc (TSX-V:N, OTCMKTS:NXTTF) has entered into a wholesale supply agreement with Kief Cannabis Company Ltd.

As per the agreement, Namaste’s subsidiary Cannmart Inc will purchase bulk cannabis products from Kief Cannabis to sell on its e-commerce platform.

READ: Namaste signs deal with CanVas MedTech on cannabis-revenue sharing

Based in Manitoba, Kief Cannabis develops artisan-crafted cannabis in small batches for the high-end recreational market.

“We believe that the online market for medical and recreational cannabis will evolve rapidly in Canada and that Namaste is well-positioned with extensive expertise to be the number one online platform for everything cannabis not only in Canada but globally,” said Namaste CEO Sean Dollinger in the company’s press release.

Namaste’s online cannabis marketplace has served more than 1.5 million customers and is looking to expand its portfolio of craft-style cannabis.

The Vancouver-based company recently signed an agreement with Cannvas MedTech Inc (CSE:MTEC) to share revenue generated through co-branding and marketing behind the its medical cannabis patient portal, known as NamasteMD, and the cannabis education platform.

Shares of Namaste rose nearly 4% to C$1.86 in Wednesday afternoon trading.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use